Spike Protein News and Research

RSS

A new SARS-CoV-2 variant (B.1.1.523) capable of escaping immune protections

A new study describes a new variant that possesses a novel combination of various concerning mutations at the spike region.

27 Sep 2021

Review of COVID-19 clinical and viral characteristics, pathogenesis, and genetics

A new review article investigates the clinical and viral characteristics, pathogenesis, as well as human genetic basis associated with COVID-19.

27 Sep 2021

SARS-CoV-2 entry inhibitors show antiviral activity

A new study used a combination of a computer-aided drug design approach and cell-based in vitro assays to identify five potential SARS-CoV-2 inhibitors.

27 Sep 2021

B cell activating anti-CD73 antibody for the immunotherapy of COVID-19

Despite the advent of numerous vaccines and the discovery of passive monoclonal antibodies for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), there remains an urgent need for definitive therapies for coronavirus disease-2019 (COVID-19) patients.

27 Sep 2021

Study shows prior COVID-19 and vaccination protects elderly against variants

In order to qualify the risk posed to the elderly, researchers from MUSE University in France began to investigate data from nursing homes that had faced outbreaks from variants of concern. Their work can be found on the medRxiv* preprint server while awaiting peer review.

27 Sep 2021

Scientists develop 'elite' antibodies capable of defeating coronavirus variants at extremely low dosage

Japanese scientists created "elite" antibodies that defeat various coronavirus variants even at an extremely low dose through a new method that accelerated the months-long process of finding such extraordinary antibody candidates to just ten days.

27 Sep 2021

Study reveals surfaces of SARS-CoV-2 spike most resistant to antibody escape

A team of international scientists has formed a consortium to map the epitope landscape of a range of therapeutic monoclonal antibodies on the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Moreover, the scientists characterized the neutralization potency of these antibodies and have investigated how emerging viral variants with spike mutations can impact antibody-mediated neutralization. They have recently published the consortium findings in the journal Science.

27 Sep 2021

Novel antibody candidate shows potent binding to diverse SARS-CoV-2 variant mutations

Twist Bioscience Corporation (Nasdaq: TWST) today reported that its internally-discovered antibody candidate TB202-3 (CoVIC-094), demonstrated potent binding to diverse SARS-CoV-2 variant mutations, including strains with the E484K, N501Y, D614G, Y453F and K417N mutations in pseudovirus assays, indicating this therapeutic antibody may be effective in treating many strains of COVID-19.

25 Sep 2021

WHO experts recommend antibody treatment for two specific groups of patients with covid-19

A treatment combining two antibodies (casirivimab and imdevimab) is recommended for two specific groups of patients with covid-19 by a WHO Guideline Development Group (GDG) panel of international experts and patients in The BMJ today.

24 Sep 2021

Inactivated egg-based Newcastle disease virus vaccine expressing SARS-CoV-2 spike protein

A new study presents initial results from a randomized, placebo-controlled phase 1/2 trial in Thailand.

24 Sep 2021

Scientists publish a detailed map of where human antibodies bind to SARS-CoV-2

Scientists at La Jolla Institute for Immunology (LJI) have published a detailed map of where human antibodies bind to SARS-CoV-2, a map that was generated by a global collaboration comparing nearly all leading clinical candidates.

24 Sep 2021

Presumed immunity in US remains below the threshold sufficient to disrupt SARS-CoV-2 transmission

Researchers have investigated publicly available data published to investigate the proportion of the US population that has become immune to SARS-CoV-2.

24 Sep 2021

Human milk antibodies elicited by vaccination show reduced activity against SARS-CoV-2 VoCs

In a study recently published on the medRxiv* preprint server, scientists from Singapore have assessed the levels of IgA-specific anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in the breast milk of women recently immunized with the second dose of an mRNA-based coronavirus disease 2019 (COVID-19) vaccine.

24 Sep 2021

Effect of prior SARS-CoV-2 infection on post-vaccination SARS-CoV-2 spike IgG antibodies

Natural infection or vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) confer considerable protection against reinfection and reduce the risk of severe Coronavirus disease 2019 (COVID-19) outcomes.

24 Sep 2021

Potential covalent SARS-CoV-2 spike protein inhibitors

There remains a significant need for new and effective drugs that can be used to treat COVID-19.

23 Sep 2021

COVID-19 vaccination and lactation

A new study evaluates the presence of antibodies in breastmilk and the immune responses of lactating women after vaccination of the COVID-19 vaccine.

23 Sep 2021

People with natural immunity and subsequent mRNA vaccination can neutralize viral particles capable of resisting vaccine-induced antibodies

New research suggests SARS-CoV-2 spike protein substitution mutations can create a replication-defective viral particle that makes the virus resistant to vaccine-induced antibodies.

23 Sep 2021

Spike Protein News and Research

A new SARS-CoV-2 variant (B.1.1.523) capable of escaping immune protections

Review of COVID-19 clinical and viral characteristics, pathogenesis, and genetics

SARS-CoV-2 entry inhibitors show antiviral activity

B cell activating anti-CD73 antibody for the immunotherapy of COVID-19

Study shows prior COVID-19 and vaccination protects elderly against variants

Scientists develop 'elite' antibodies capable of defeating coronavirus variants at extremely low dosage

Study reveals surfaces of SARS-CoV-2 spike most resistant to antibody escape

Novel antibody candidate shows potent binding to diverse SARS-CoV-2 variant mutations

WHO experts recommend antibody treatment for two specific groups of patients with covid-19

Inactivated egg-based Newcastle disease virus vaccine expressing SARS-CoV-2 spike protein

Scientists publish a detailed map of where human antibodies bind to SARS-CoV-2

Presumed immunity in US remains below the threshold sufficient to disrupt SARS-CoV-2 transmission

Human milk antibodies elicited by vaccination show reduced activity against SARS-CoV-2 VoCs

Effect of prior SARS-CoV-2 infection on post-vaccination SARS-CoV-2 spike IgG antibodies

Potential covalent SARS-CoV-2 spike protein inhibitors

COVID-19 vaccination and lactation

People with natural immunity and subsequent mRNA vaccination can neutralize viral particles capable of resisting vaccine-induced antibodies

Varying immune responses after single dose of Pfizer and AstraZeneca COVID-19 vaccines

The impact of multiple sclerosis therapy on COVID-19 vaccine efficacy

Antibody kinetics in recovered COVID-19 patients

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News